OS Therapies closes $8M asset acquisition from Ayala; eliminates $20M milestones, cuts royalty to 1.5%

OS Therapies Inc

Total consideration $8M: $400k cash to Ayala, $100k to third party, $7.5M in stock (4,774,637 shares at VWAP).
Eliminated $3.5M Biologics License filing milestone and $16.5M in sales milestones for OST-HER2.
Royalty on OST-HER2, ADXS-503, ADXS-504 reduced from 10% to 1.5% of net sales (to Univ. of Pennsylvania).
Added three clinical-stage candidates (OST-AXAL for HPV, OST-503 for NSCLC, OST-PSA for prostate) and 8 preclinical constructs.
Issued 2,164,215 shares and a warrant for 2,166,381 shares (exercise $0.001, 3-yr term); additional 444,041 shares pending stockholder approval.

item 2.01 item 3.02 item 1.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.